Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

CML

Trial Name: Studying Interventions For Managing Patients With Chronic Myeloid Leukemia In Chronic Phase: The 5-Year Prospective Cohort Study (Simplicity).

Protocol ID: Simplicity Study

Eligibility:

Inclusion
  • Newly-diagnosed CP-CML patients
Retrospective patients must have been diagnosed after January 1, 2008
Prospective patients can be enrolled up to 6 months after the date of diagnosis
  • 18 years of age or older at the time of diagnosis
  • Receiving treatment with one of the following TKIs for first-line treatment:
Imatinib
Dasatinib
Nilotinib
  • Receiving treatment at medical practice (eg. Community-based, office-based, hospital-based, academic setting, oncology center).
 
Exclusion

Patients who are participating in a clinical trial for CML treatment will be excluded.

Enrollment: • The study will include about 1400 patients enrolled at about 200 sites worldwide in countries across America and Europe; the study is expected to continue through June 2017.

Benefits:

The data collected during this study will help to improve knowledge and understanding of the management of patients with CP-CML, but will have no impact on the treatment decisions made by your study doctor.

Contact:

These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353.

Created: Dec 1, 2011

Updated: Feb 24, 2014

« Return to Trials